{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:53:40Z","timestamp":1794110020213,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Staphylococcus aureus<\/jats:italic> bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15\u201350%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated complications. Dalbavancin is a lipoglycopeptide with potent activity against <jats:italic>Staphylococcus<\/jats:italic> and a long half-life, making it an appealing potential therapy for <jats:italic>S. aureus<\/jats:italic> bacteremia without the need for durable central venous access.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>DOTS is a phase 2b, multicenter, randomized, assessor-blinded, superiority, active-controlled, parallel-group trial. The trial will enroll 200 adults diagnosed with complicated <jats:italic>S. aureus<\/jats:italic> bacteremia, including definite or possible right-sided infective endocarditis, who have been treated with effective antibiotic therapy for at least 72 h (maximum 10 days) and with subsequent clearance of bacteremia prior to randomization to study treatment. Subjects will be randomized 1:1 to complete their antibiotic treatment course with either two doses of dalbavancin on days 1 and 8, or with a total of 4\u20138 weeks of standard intravenous antibiotic therapy. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versus standard of care. Key secondary endpoints include quality of life outcomes and pharmacokinetic analyses of dalbavancin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The DOTS trial will establish whether dalbavancin is superior to standard parenteral antibiotic therapy for the completion of treatment of complicated <jats:italic>S. aureus<\/jats:italic> bacteremia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>US National Institutes of Health <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04775953\">NCT04775953<\/jats:ext-link>. Registered on 1 March 2021<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06370-1","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:13:28Z","timestamp":1652685208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Nicholas A.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varduhi","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Beresnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Doernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urania","family":"Rappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-9010","authenticated-orcid":false,"given":"Thomas L.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Antibacterial Resistance Leadership Group (ARLG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"25","key":"6370_CR1","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.044913","volume":"141","author":"ASV Shah","year":"2020","unstructured":"Shah ASV, McAllister DA, Gallacher P, Astengo F, P\u00e9rez JAR, Hall J, et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis. Circulation. 2020;141(25):2067\u201377.","journal-title":"Circulation."},{"issue":"12","key":"6370_CR2","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1086\/648442","volume":"49","author":"WI El Atrouni","year":"2009","unstructured":"El Atrouni WI, Knoll BM, Lahr BD, Eckel-Passow JE, Sia IG, Baddour LM. Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population-based study. Clin Infect Dis. 2009;49(12):e130\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6370_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"6370_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"6370_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.4065\/81.9.1159","volume":"81","author":"DG Maki","year":"2006","unstructured":"Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81(9):1159\u201371.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"6370_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jpeds.2013.10.025","volume":"164","author":"CM Takemoto","year":"2014","unstructured":"Takemoto CM, Sohi S, Desai K, Bharaj R, Khanna A, McFarland S, et al. Hospital-associated venous thromboembolism in children: incidence and clinical characteristics. J Pediatr. 2014;164(2):332\u20138.","journal-title":"J Pediatr"},{"key":"6370_CR7","doi-asserted-by":"crossref","unstructured":"Ajaka L, Heil E, Schmalze S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel). 2020;9(10):700.","DOI":"10.3390\/antibiotics9100700"},{"issue":"23","key":"6370_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379.","journal-title":"N Engl J Med"},{"issue":"5","key":"6370_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","volume":"62","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545\u201351.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6370_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407\u201315.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6370_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40121-021-00402-0","volume":"10","author":"PL Gonzalez","year":"2021","unstructured":"Gonzalez PL, Rappo U, Mas Casullo V, Akinapelli K, McGregor JS, Nelson J, et al. Safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSI): nephrotoxicity rates compared with vancomycin: a post hoc analysis of three clinical trials. Infect Dis Ther. 2021;10(1):471\u201381.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"6370_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14740338.2021.1935864","volume":"20","author":"N Monteagudo-Martinez","year":"2021","unstructured":"Monteagudo-Martinez N, Solis-Garcia Del Pozo J, Ikuta I, Galindo M, Jordan J. Systematic review and metaanalysis on the safety of dalbavancin. Expert Opin Drug Saf. 2021;20(9):1095\u2013107.","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"6370_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpdd.695","volume":"9","author":"TJ Carrothers","year":"2020","unstructured":"Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2020;9(1):21\u201331.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"6370_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374\u201380.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6370_CR15","first-page":"ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open forum. Infect Dis Ther. 2019;6(1):ofy331.","journal-title":"Infect Dis Ther"},{"key":"6370_CR16","doi-asserted-by":"crossref","unstructured":"Cooper MM, Preslaski CR, Shihadeh KC, Hawkins KL, Jenkins TC. Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review. Open forum. Infect Dis Ther. 2021;8(11).","DOI":"10.1093\/ofid\/ofab486"},{"issue":"10","key":"6370_CR17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/379015","volume":"37","author":"E Seltzer","year":"2003","unstructured":"Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298\u2013303.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6370_CR18","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/cid\/ciy766","volume":"68","author":"SB Doernberg","year":"2019","unstructured":"Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, et al. Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2019;68(10):1691\u20138.","journal-title":"Clin Infect Dis"},{"key":"6370_CR19","unstructured":"(CDC) CfDC. NHSN Patient Safety Component Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection) 2018 [Available from: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/pcsmanual_current.pdf."},{"key":"6370_CR20","volume-title":"National Healthcare Safety Network (NHSN) patient safety component manual","author":"Centers for Disease Control (CDC)","year":"2020","unstructured":"Centers for Disease Control (CDC). National Healthcare Safety Network (NHSN) patient safety component manualCenters for Disease Control and Prevention; 2020."},{"issue":"15","key":"6370_CR21","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435\u201386.","journal-title":"Circulation."},{"issue":"3","key":"6370_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361\u20137.","journal-title":"Clin Infect Dis"},{"key":"6370_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","volume":"15","author":"D Wong","year":"2016","unstructured":"Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016;15:27.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2","key":"6370_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44(2):190\u20136.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6370_CR25","first-page":"ofy042","volume":"5","author":"NA Turner","year":"2018","unstructured":"Turner NA, Moehring R, Sarubbi C, Wrenn RH, Drew RH, Cunningham CK, et al. Influence of reported penicillin allergy on mortality in MSSA bacteremia. Open forum. Infect Dis Ther. 2018;5(3):ofy042.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"6370_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"6370_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/phar.2070","volume":"38","author":"TT Timbrook","year":"2018","unstructured":"Timbrook TT, Caffrey AR, Luther MK, Lopes V, LaPlante KL. Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy. 2018;38(2):189\u201396.","journal-title":"Pharmacotherapy."},{"issue":"10121","key":"6370_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","volume":"391","author":"GE Thwaites","year":"2018","unstructured":"Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668\u201378.","journal-title":"Lancet."},{"issue":"6","key":"6370_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/597031","volume":"48","author":"SE Cosgrove","year":"2009","unstructured":"Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48(6):713\u201321.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6370_CR30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6370_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","volume":"61","author":"SR Evans","year":"2015","unstructured":"Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800\u20136.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6370_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","volume":"8","author":"SR Evans","year":"2016","unstructured":"Evans SR, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation. Stat Biopharm Res. 2016;8(4):386\u201393.","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"6370_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/cid\/ciaa611","volume":"73","author":"HA King","year":"2021","unstructured":"King HA, Doernberg SB, Miller J, Grover K, Oakes M, Ruffin F, et al. Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: a qualitative descriptive study and concept elicitation phase to inform measurement of patient-reported quality of life. Clin Infect Dis. 2021;73(2):237\u201347.","journal-title":"Clin Infect Dis"},{"key":"6370_CR34","doi-asserted-by":"publisher","unstructured":"King HA, Doernberg SB, Grover K, Miller J, Oakes M, Wang T-W, et al. Patients' experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: results from cognitive interviews to inform assessment of health-related quality of life. Open Forum Infect Dis. 2021:9(2). ePub available from:\u00a0https:\/\/doi.org\/10.1093\/ofid\/ofab622.","DOI":"10.1093\/ofid\/ofab622"},{"key":"6370_CR35","unstructured":"EuroQoL Group. 2009. [Available from; https:\/\/euroqol.org\/eq-5d-instruments\/sample-demo\/"},{"key":"6370_CR36","unstructured":"PROMIS Organization. 2016 [Available from: http:\/\/www.healthmeasures.net\/administrator\/components\/com_instruments\/uploads\/Global%20Health%20Scale%20v1.2%2008.22.2016.pdf."},{"issue":"6","key":"6370_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/009286150704100606","volume":"41","author":"SR Evans","year":"2007","unstructured":"Evans SR, Li L, Wei L. Data monitoring in clinical trials using prediction. Drug Inform J. 2007;41(6):733\u201342.","journal-title":"Drug Inform J"},{"issue":"4","key":"6370_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1198\/sbr.2009.0041","volume":"1","author":"L Li","year":"2009","unstructured":"Li L, Evans SR, Uno H, Wei LJ. Predicted interval plots (PIPS): a graphical tool for data monitoring of clinical trials. Stat Biopharm Res. 2009;1(4):348\u201355.","journal-title":"Stat Biopharm Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06370-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:17:33Z","timestamp":1652685453000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6370"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06370-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilizes a centralized institutional review board (IRB) through WCG. The study protocol and centralized IRB conclusion will be reviewed and adopted by each site\u2019s relevant local IRB prior to participation. All subjects require written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Consent for publication was sought and approved by all listed authors, study sponsor (NIH\/ARLG), and Abbvie (which provided study drug). Model informed consent form available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors report no competing interests with the work submitted. For full disclosure, the authors report the following outside financial activities: Vance G. Fowler reports receiving consultancy fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, Aridis, and Roche; grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Basilea, and Janssen; royalties from UptoDate; stock options in Valanbio and ArcBio; and an editorial stipend from the Infectious Diseases Society of America. Thomas L. Holland reports serving on the scientific advisory board for Motif Bio, consulting for Basilea, Motif Bio, Genentech, and Theravance. Heather King reports receiving consultancy feeds from Merck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"407"}}